DNLI - Denali Therapeutics: Another Near-Term Capital Gain Prospect Market-Makers See As Underpriced

• Comparisons with DNLI are from hundreds of biotech product developers viewed continually by institutional investors as capital gain prospects. Including some held to be underpriced just days ago.
• Values are based on how market professionals protect their own capital, put at risk in order to fill multi-million-$ trade orders placed by institutions managing multi-billion-$ portfolios.
• Those client trade orders must be executed quickly and quietly or run the risk of being front-run by hordes of opportunists. Often market-makers must create short positions on their books.
• But they lay off the risk of rising prices on those shorts to other speculator-pros, all for a cost, in separate but related markets for derivatives.
• What the cost of that protection is and how it is provided tell what the involved, well-informed players think coming prices can be. Implied price-range forecasts.

For further details see: